US insurers are covering the treatment, despite high price.
Sales of MS and eczema drugs could top $4bn by 2022
Biotech looks for funding and long-term development partner
Success with ozanimod would justify $7.2 billion outlay for Receptos.
Firm searches for new leader, chairman takes over on interim basis.
Court invalidates patents on latest Copaxone formulation.
Biotech’s R&D operations will be spun off.
A round-up of this week’s digital healthcare news. Marco Ricci reports.
Biogen could also pay royalties to Forward.